CD274 and cervical carcinoma: PD-L1 inhibitor durvalumab local injection substantially alters the immune microenvironment of cervical cancer and their draining lymph nodes, including reducing the presence of Tregs and PD-L1-positive macrophages in tumors, thereby enhancing T cell-mediated antitumor activity (84).